Zevra Therapeutics (ZVRA) Profit After Tax Growth (5y) (2019 - 2026)
Zevra Therapeutics (ZVRA) Profit After Tax Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Zevra Therapeutics | 570.04 Mn | 369.43 Mn | 34.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.54% |
| Dec 31, 2025 | 35.13% |
| Sep 30, 2025 | 28.97% |
| Jun 30, 2025 | 144.27% |
| Mar 31, 2025 | 11.64% |
| Dec 31, 2024 | -42.71% |
| Sep 30, 2024 | -66.63% |
| Jun 30, 2024 | -16.57% |
| Mar 31, 2024 | -6.22% |
| Dec 31, 2023 | -5.58% |
| Sep 30, 2023 | -11.44% |
| Jun 30, 2023 | 23.77% |
| Mar 31, 2023 | 12.80% |
| Dec 31, 2022 | 20.53% |
| Dec 31, 2021 | 22.92% |
| Sep 30, 2021 | 33.39% |
| Jun 30, 2021 | -8.68% |
| Mar 31, 2021 | -28.54% |
| Dec 31, 2020 | 12.00% |
| Sep 30, 2020 | 20.94% |